Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years
- ANTHONY S. FAUCI, M.D.;
- BARTON F. HAYNES, M.D.;
- PAUL KATZ, M.D.; and
- SHELDON M. WOLFF, M.D.
Abstract
Eighty-five patients with Wegener's granulomatosis were studied for 21 years at the National Institutes of Health. Patients were treated with a protocol consisting of cyclophosphamide, 2 mg/kg body weight · d, together with prednisone, 1 mg/kg body weight · d, followed by conversion of the prednisone to an alternate-day regimen. Complete remissions were achieved in 79 of 85 patients (93%). The mean duration of remission for living patients was 48.2 (± 3.6) months. Twenty-three patients are off all therapy for a mean duration of 35.3 (± 6.3) months without therapy. This study provides a prospective experience with Wegener's granulomatosis and shows that long-term remissions can be induced and maintained in an extremely high number of patients by the combination of daily cyclophosphamide and alternate-day prednisone therapy.
Article and Author Information
-
▸From the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda. Maryland.
-
▸Requests for reprints should be addressed to Anthony S. Fauci, M.D.; Building 10, Room 11B-13, National Institutes of Health; Bethesda, MD 20205.
- ©1983 American College of Physicians
RSS Feeds









